IP Library › Granted Patent US 8,546,368
Granted Patent B2
US 8,546,368 · App. 11/675,570 · Granted Oct 1, 2013

Pyrazoloquinolones are potent PARP inhibitors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,546,368
App. No.
11/675,570
Granted
Oct 1, 2013
Kind
B2
Abstract

Compounds of Formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I), methods of treatment comprising compounds of Formula (I), and methods of inhibiting the PARP enzyme comprising compounds of Formula (I).

Claims (1)

1. A compound which is 7,9-dimethyl-1,2,3,4,6,7-hexahydro-5H-pyrazolo[3,4-h]-1,6-naphthyridin-5-one.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2013
From: ABBOTT LABORATORIES
To: ABBVIE INC.
Reel/Frame 030231/0808 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2007
From: PENNING, THOMAS D.; ZHU, GUI-DONG; GANDHI, VIRAJKUMAR B.; GONG, JIANCHUM; GIRANDA, VINCENT L.
To: ABBOTT LABORATORIES
Reel/Frame 019537/0171 →